Document is current
Any future updates will be listed below
-
Authors
Hartmann, Sylvia
Yasmeen, Summaira https://orcid.org/0000-0001-5470-2081
Jacobs, Benjamin M. https://orcid.org/0000-0002-6023-6010
Denaxas, Spiros
Pirmohamed, Munir https://orcid.org/0000-0002-7534-7266
Gamazon, Eric R. https://orcid.org/0000-0003-4204-8734
Caulfield, Mark J. https://orcid.org/0000-0001-9295-3594
,
Hemingway, Harry https://orcid.org/0000-0003-2279-0624
Pietzner, Maik https://orcid.org/0000-0003-3437-9963
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
- License Information
-
More Information
Article History
Received: 6 January 2023
Accepted: 21 September 2023
First Online: 12 October 2023
Competing interests
: Mu. P. has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly, and Novartis); and a Ph.D. studentship jointly funded by EPSRC and Astra Zeneca. Mu. P. also has unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb. Mu. P. has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT ( ). None of the funding outlined above is related to the current paper. None of the other authors have competing interests.
